RF Ablation of Cancer and Microbial Pathogens
Keywords: Radiowaves, Cancer, Pathogens, Ether, TB, HIV
The theory of RF ablation of cells is based on varying fundamental frequencies of atoms. This theory is based on a new atomic structure that defines elementary charge and measures the entity we call mass. A paradigm shift in the way we look at recognition on the sub atomic scale has now been opened. Cancer tumors and microbial cells have been ablated with radio waves in-vitro and in-vivo. The docking ability of a nanoparticle to a cell to be ablated has been achieved by use of immuno-stealth-liposomes. Leaky tumor cells easily incorporate liposomes. Permeation of endothelium and retention of liposomes has been achieved for different tumor types in mice by passive targeting. Antibody receptors of the microbial cells allow for target specific locking of immunoliposomes in-vivo. Thus for the first time moving microbial pathogens in peripheral blood of guinea pigs have been ablated with RF fired from outside the body. An alternative to chemotherapy, gamma knife therapy, antibiotics, vaccines and gene therapy is now available for patients suffering from MDR, XDR and metastases. These conventional treatments are besieged with problems of antigenic drift and shift. Furthermore, side effects of chemotherapy are devastating for patients. Autoimmunity is the spanner in the works for any form of protein based therapy. Gene therapy is unable to shut down different loci of oligonucleotides in selective strands of DNA or RNA in and across tissues in the whole body. Moreover, pathogens hide in host cells and evade the immune surveillance system. These pitfalls are overcome by RF that kill the host cells harboring hideaway pathogens. This new way to treat disease is affordable and free from side effects when compared to other conventional treatments where cytotoxicity to bystander normal cells is invariably present. RF treatment restores normalcy within a week to ten days in animal models. RF treatment will prove to be the future for therapeutics.